HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Piramal Pharma Ltd Stock Comparison

Alivus Life Sciences Ltd vs Piramal Pharma Ltd Stock Comparison

Last Updated on: May 20, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1138 as of 20 May 10:01.
  • The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2024 . This represents a CAGR of 0.0% over 4 yearsThe P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 991.5 on March 2024 . This represents a CAGR of 0.00% over 1 years.
  • The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 4 yearsThe Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 17052 crore on March 2024 . This represents a CAGR of 44.51% over 2 years.
  • The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Piramal Pharma Ltd for the Mar '25 is ₹ 2812 crore as compare to the Dec '24 revenue of ₹ 2233 crore. This represent the growth of 25.92%.
  • The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Piramal Pharma Ltd for the Mar '25 is ₹ 619.24 crore as compare to the Dec '24 ebitda of ₹ 366.92 crore. This represent the growth of 68.77%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Piramal Pharma Ltd changed from ₹ -98.58 crore to ₹ 153.5 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 58.56 % on March 2024 . This represents a CAGR of -1.60% over 3 yearsThe Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 3.72 % on March 2024 . This represents a CAGR of -40.95% over 3 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018.
  • A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited.
  • The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.

About Piramal Pharma Ltd

  • Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
  • It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
  • In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
  • It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

Alivus Life Sciences Ltd News Hub

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

News

Glenmark Life Sciences renamed as Alivus Life Sciences

Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking a...

Read more

20 Jan 2025 10:18

Piramal Pharma Ltd News Hub

News

Board of Piramal Pharma recommends final dividend

Piramal Pharma announced that the Board of Directors of the Company at its meeting held on...

Read more

15 May 2025 10:18

News

Piramal Pharma's Turbhe facility successfully completes USFDA inspection

Piramal Pharma announced that the USFDA has issued an Establishment Inspection Report (EIR...

Read more

12 May 2025 12:47

News

Piramal Pharma gains after receiving EIR for Turbhe facility from USFDA

According to the company's exchange filing, the US FDA conducted a general Good Manufactur...

Read more

12 May 2025 15:39

News

Piramal Pharma to conduct board meeting

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 14 May 2025...

Read more

30 Apr 2025 10:45

News

Piramal Pharma's Telangana unit starts production of general anesthesia drug Sevoflurane

This was achieved by creating capacity for Sevoflurane manufacture at the Digwal facility ...

Read more

02 Apr 2025 11:25

News

Piramal Pharma Ltd Spurts 3.8%

Piramal Pharma Ltd rose 3.8% today to trade at Rs 229.65. The BSE Healthcare index is up 0...

Read more

21 Mar 2025 09:30

SWOT Analysis Of Piramal Pharma Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Piramal Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Piramal Pharma Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Piramal Pharma Ltd?

Market cap of Alivus Life Sciences Ltd is 14,052 Cr while Market cap of Piramal Pharma Ltd is 27,257 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Piramal Pharma Ltd?

The stock performance of Alivus Life Sciences Ltd and Piramal Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Piramal Pharma Ltd?

As of May 20, 2025, the Alivus Life Sciences Ltd stock price is INR ₹1145.9. On the other hand, Piramal Pharma Ltd stock price is INR ₹205.6.

How do dividend payouts of Alivus Life Sciences Ltd and Piramal Pharma Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Piramal Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions